Sangamo Therapeutics, Inc. (NASDAQ:SGMO) VP Curt A. Herberts III sold 16,630 shares of the firm’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $16.13, for a total value of $268,241.90. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) traded down $0.10 during trading hours on Thursday, reaching $16.35. 1,735,100 shares of the company were exchanged, compared to its average volume of 1,314,902. Sangamo Therapeutics, Inc. has a 52 week low of $2.65 and a 52 week high of $18.40. The company has a quick ratio of 5.64, a current ratio of 5.64 and a debt-to-equity ratio of 0.02.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.04. Sangamo Therapeutics had a negative net margin of 157.66% and a negative return on equity of 31.81%. The business had revenue of $11.81 million for the quarter, compared to analyst estimates of $10.37 million. During the same period in the previous year, the company earned ($0.27) earnings per share. The business’s revenue for the quarter was up 333.0% on a year-over-year basis. sell-side analysts predict that Sangamo Therapeutics, Inc. will post -0.73 EPS for the current fiscal year.

Several research analysts recently commented on the company. Barclays started coverage on Sangamo Therapeutics in a research report on Wednesday, November 22nd. They issued an “overweight” rating and a $20.00 price target for the company. Jefferies Group restated a “buy” rating and set a $18.00 target price on shares of Sangamo Therapeutics in a research report on Friday, October 13th. Wedbush restated a “hold” rating and set a $6.00 target price on shares of Sangamo Therapeutics in a research report on Wednesday, November 15th. Wells Fargo & Company restated an “outperform” rating and set a $30.00 target price (up previously from $20.00) on shares of Sangamo Therapeutics in a research report on Tuesday, September 5th. Finally, Zacks Investment Research upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research report on Wednesday, November 15th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $17.83.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SGMO. Teachers Advisors LLC boosted its holdings in Sangamo Therapeutics by 9.8% in the first quarter. Teachers Advisors LLC now owns 180,858 shares of the biopharmaceutical company’s stock valued at $940,000 after purchasing an additional 16,130 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Sangamo Therapeutics by 8.4% in the first quarter. Vanguard Group Inc. now owns 3,087,650 shares of the biopharmaceutical company’s stock valued at $16,056,000 after purchasing an additional 239,544 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Sangamo Therapeutics by 3.1% in the first quarter. Geode Capital Management LLC now owns 633,964 shares of the biopharmaceutical company’s stock valued at $3,296,000 after purchasing an additional 19,331 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Sangamo Therapeutics by 0.4% in the first quarter. Dimensional Fund Advisors LP now owns 128,764 shares of the biopharmaceutical company’s stock valued at $670,000 after purchasing an additional 513 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its holdings in Sangamo Therapeutics by 5.6% in the first quarter. Schwab Charles Investment Management Inc. now owns 265,735 shares of the biopharmaceutical company’s stock valued at $1,382,000 after purchasing an additional 14,022 shares during the last quarter. 64.35% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This news story was posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/12/07/sangamo-therapeutics-inc-sgmo-vp-sells-268241-90-in-stock.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Insider Buying and Selling by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.